Peer-reviewed veterinary case report
Dog with lymphoblastic lymphoma treated by spinal chemotherapy
By Lyseight, Filipa Louise Simões et al.·Published in Frontiers in veterinary science·2023·Oncology Service, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intrathecal chemotherapy for the management of lymphoblastic lymphoma in a 4-year-old dog: a case report.
- Species:
- dog
Plain-English summary
A 4-year-old male cross-breed dog was brought in with severe lethargy, weakness in his back legs, and trouble urinating. The vet found swollen lymph nodes and diagnosed him with multicentric lymphoblastic B-cell lymphoma, a type of cancer. After starting chemotherapy, the dog initially improved but then showed signs of neurological issues a month later. He received intrathecal chemotherapy (injections into the spinal area) along with other medications, which helped him feel better within a day and kept him symptom-free for about three weeks. Unfortunately, he later experienced a relapse and was humanely euthanized nine weeks after his diagnosis.
People also search for: dog lymphoma treatment · dog lethargy and weakness · intrathecal chemotherapy for dogs · lymphoma in dogs prognosis · dog urinary retention causes
Abstract
Intrathecal chemotherapy is used in human medicine for the treatment or prophylaxis of CNS hematopoietic neoplasia. However, the clinical benefits in veterinary medicine have been scarcely documented. A 4-year-old male entire cross-breed dog presented with a 24-h history of severe lethargy, pelvic limb weakness, and urinary retention. Examination revealed generalized peripheral lymphadenomegaly, and the neurological findings were suggestive of a myelopathy in the region of T3-L3. Following the diagnosis of multicentric lymphoblastic B-cell lymphoma (stage Vb), a modified L-LOP with cytosine arabinoside was started, and complete clinical remission was achieved. After 4 weeks, there was acute neurological deterioration (spinal pain and proprioceptive deficits) without peripheral lymphadenomegaly. MRI findings and CSF analysis were consistent with meningeal and spinal cord lymphoma infiltration at the level of L3. Intrathecal chemotherapy (cytosine arabinoside and methotrexate) were administered in the cisterna magna with systemic dexamethasone and analgesia. Clinical signs were resolved within 24 h, and the patient remained asymptomatic for 3.5 weeks. After this period, CNS relapse (proprioceptive deficits and severe thoracolumbar pain) was suspected, and repeat intrathecal chemotherapy was declined. The patient was humanely euthanized 9 weeks after the initial diagnosis. This is the first report on the clinical benefit of intrathecal chemotherapy with a combination of methotrexate and cytarabine for the management of CNS lymphoma in dogs. Based on our case, intrathecal chemotherapy with methotrexate and cytarabine can induce a short-lasting CNS clinical remission (3 weeks).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37732143/